Literature DB >> 28751765

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

E J Cheadle, G Lipowska-Bhalla, S J Dovedi, E Fagnano, C Klein, J Honeychurch, T M Illidge.   

Abstract

This corrects the article DOI: 10.1038/leu.2016.352.

Entities:  

Year:  2017        PMID： 28751765      PMCID： PMC7609297          DOI： 10.1038/leu.2017.218

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


Correction to: Leukemia (2017) 31, 1611–1621; doi:10.1038/leu.2016.352; published online 3 January 2017 Following the publication of this article, it was noted that the HTML version contained the wrong AAP date. The correct AAP date is 28 November 2016.
  3 in total

1.  Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.

Authors:  Fulvia Vascotto; Jutta Petschenka; Kerstin C Walzer; Mathias Vormehr; Magdalena Brkic; Stefan Strobl; Roman Rösemann; Mustafa Diken; Sebastian Kreiter; Özlem Türeci; Ugur Sahin
Journal:  Oncoimmunology       Date:  2019-04-19       Impact factor: 8.110

2.  TLR7 modulating B-cell immune responses in the spleen of C57BL/6 mice infected with Schistosoma japonicum.

Authors:  Haixia Wei; Hongyan Xie; Jiale Qu; Anqi Xie; Shihao Xie; He Huang; Jiajie Li; Chao Fang; Feihu Shi; Huaina Qiu; Yanwei Qi; Xu Tian; Quan Yang; Jun Huang
Journal:  PLoS Negl Trop Dis       Date:  2021-11-17

3.  The Prognostic Value of Toll-Like Receptors in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Shrabon Hasnat; Roosa Hujanen; Bright I Nwaru; Tuula Salo; Abdelhakim Salem
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.